Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Yoshinobu Kinugawa"'
Autor:
Charles E Grimshaw, Andy Jennings, Ruhi Kamran, Hikaru Ueno, Nobuhiro Nishigaki, Takuo Kosaka, Akiyoshi Tani, Hiroki Sano, Yoshinobu Kinugawa, Emiko Koumura, Lihong Shi, Koji Takeuchi
Publikováno v:
PLoS ONE, Vol 11, Iss 6, p e0157509 (2016)
Trelagliptin (SYR-472), a novel dipeptidyl peptidase-4 inhibitor, shows sustained efficacy by once-weekly dosing in type 2 diabetes patients. In this study, we characterized in vitro properties of trelagliptin, which exhibited approximately 4- and 12
Externí odkaz:
https://doaj.org/article/c2f5e8f538fd4b978e232dde76104e2e
Autor:
Hiromi Rakugi, Kohei Shimizu, Yoshinobu Kinugawa, Yuhei Sano, Yuya Nishiyama, Souhei Terashio
Publikováno v:
Blood Pressure Monitoring. 23:91-102
Objective The efficacy and safety of triple therapy with azilsartan (AZI), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) compared with dual therapy with AZI/AML or HCTZ monotherapy were evaluated in Japanese essential hypertensive patient
Publikováno v:
Diabetes, Obesity & Metabolism
This randomized, double‐blind, phase III study evaluated the efficacy and safety of once‐daily treatment with alogliptin (25 mg once daily), alone or with metformin hydrochloride (500 mg once daily or 250 mg twice daily), in Japanese patients wit
Autor:
Yoshinobu Kinugawa, Lihong Shi, Charles E. Grimshaw, Takuo Kosaka, Emiko Koumura, Andrew John Jennings, Koji Takeuchi, Ruhi Kamran, Nobuhiro Nishigaki, Hiroki Sano, Hikaru Ueno, Akiyoshi Tani
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 6, p e0157509 (2016)
PLoS ONE, Vol 11, Iss 6, p e0157509 (2016)
Trelagliptin (SYR-472), a novel dipeptidyl peptidase-4 inhibitor, shows sustained efficacy by once-weekly dosing in type 2 diabetes patients. In this study, we characterized in vitro properties of trelagliptin, which exhibited approximately 4- and 12
Autor:
Etsuko Kawashima, Yoshinobu Kinugawa
Publikováno v:
Nucleic Acids Symposium Series. 2:19-20
An approach to a synthesis of stereoselective 5'-monodeuterated nucleoside combined with 13C label is described. A preparation of (5R)-D-[5-(2)H1;5-(13)C]ribose derivative of 1,2:5,6-di-O-isopropyliden-alpha-D-allofranose was successfully achieved by